Multimodal Vasopressor Strategy in Septic Shock

Shock, Septic Clinical Trial

Official title: Simultaneous Administration of Norepinephrine, Angiotensin II, and Vasopressin in Septic Shock Patients

Status Recruiting

Clinical Trial Summary

The goal of this prospective randomized controlled trial is to compare the effects of classic stepwise vs. early balanced multimodal vasopressor strategies in septic shock.

Clinical Trial Description

CONTROL GROUP(Classic stepwise vasopressor administration): Patients will be started on norepinephrine with increases of 0.05-0.1 mcg/kg/min up to 0.5 mcg/kg/min, followed by vasopressin (administered at a fixed dose of 0.03 IE/min). If MAP remains < 65 mmHg, norepinephrine will be titrated above dose of 0.5 mcg/kg/min until MAP ≥ 65 mmHg. Initiation of additional vasoactive drugs (epinephrine, methylene blue, angiotensin II, dobutamine, or dopamine) as per clinical team decision. EXPERIMENTAL GROUP(Balanced multimodal vasopressor administration): Early, simultaneous start of norepinephrine, angiotensin II and vasopressin at equivalent starting doses (equivalent to approximately 0.05 mcg/kg/min of norepinephrine). Increments of 0.05 mcg/kg/min of equivalent doses of all three vasopressors every 3-5 min until MAP ≥ 65 mmHg is reached (vasopressin will be administered at a maximum dose of 0.03 IE/min). ;

Related Conditions & MeSH terms

• Shock
• Shock, Septic

• NCT number: NCT06155812
• Study type: Interventional
• Source: University Medical Centre Maribor
• Contact: Žiga Kalamar, MD
• Phone: +386 2 321 2471
• Email: ziga.kalamar94@gmail.com
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: November 3, 2023
• Completion date: November 2026